Inhibition of airway reactivity by nifedipine in patients with coronary artery disease.
Nine patients with coronary artery disease were challenged with aerosolized methacholine before and 3 days after the daily oral administration of 30 mg of nifedipine. Resting airway tone appeared to be generally unaffected by nifedipine, as there were no significant changes in the baseline ventilatory functions. Serial measurements of spirometry and airway resistance were made after cumulative methacholine doses of 1.25, 3.75, and 8.75 mg. Identical doses of methacholine induced smaller changes in specific airway conductance (p less than 0.02), airway resistance (p less than 0.001), FEV1 (p less than 0.02), and FEF25-75% (p less than 0.01) after nifedipine therapy than before. These differences were significant at all methacholine dosage levels by paired t test except for FEV1 at the 3.75 mg dose. This study demonstrated that the bronchospastic response to methacholine in patients with coronary artery disease is reduced after the administration of nifedipine. This salutary effect on ventilatory function may be of importance to cardiac patients with concomitant chronic airway obstruction who are intolerant of beta-adrenergic blocking agents.
D000403:Airway Resistance / Q000187:drug effects; D001985:Bronchial Provocation Tests; D001986:Bronchial Spasm / Q000517:prevention & control*; D003327:Coronary Disease / Q000188:drug therapy*; D005541:Forced Expiratory Volume; D006801:Humans; D008297:Male; D008450:Maximal Midexpiratory Flow Rate; D008688:Methacholine Compounds; D008875:Middle Aged; D009543:Nifedipine / Q000627:therapeutic use*; D011725:Pyridines / Q000627:therapeutic use*; D014797:Vital Capacity
D008688:Methacholine Compounds; D011725:Pyridines; D009543:Nifedipine